Proteomics International is applying its Promarker™ technology platform to create new diagnostic tests for chronic diseases with unmet medical need.
The Promarker™ platform uses mass spectrometry-based technology to identify the proteins that can be used as ‘a fingerprint’ of disease or other conditions.
Biomarker discovery, verification and analytical validation is available as a fee for service model, or through a collaborative partnership with Proteomics International. Read more.
The Promarker™ platform was used to discover, verify and analytically validate the panel of protein biomarkers for diabetic kidney disease. This technology platform continues to be used in the company’s certified laboratories as the commercialised test PromarkerD.
See Promarker™ Pipeline for the areas of unmet need currently being investigated by Proteomics International.